

Fritz C Eilber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8777992/publications.pdf>

Version: 2024-02-01

73
papers

2,931
citations

136950

32
h-index

168389

53
g-index

74
all docs

74
docs citations

74
times ranked

1911
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 84-94.	7.0	22
2	Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies. <i>Current Treatment Options in Oncology</i> , 2021, 22, 9.	3.0	4
3	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. <i>Medical Physics</i> , 2021, 48, 3262-3372.	3.0	11
4	High ^{68}Ga -FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	3
5	Evaluating Thresholds to Adopt Hypofractionated Preoperative Radiotherapy as Standard of Care in Sarcoma. <i>Sarcoma</i> , 2021, 2021, 1-8.	1.3	6
6	Chemotherapy and Survival in Patients with Primary High-Grade Extremity and Trunk Soft Tissue Sarcoma. <i>Cancers</i> , 2020, 12, 2389.	3.7	9
7	Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. <i>Physics in Medicine and Biology</i> , 2020, 65, 175006.	3.0	38
8	A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 1829-1836.	7.0	63
9	[^{18}F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , 2020, 10, 122.	2.5	8
10	Low Rates of Chemotherapy Use for Primary, High-Grade Soft Tissue Sarcoma: A National Cancer Database Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1055-1065.	4.9	6
11	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	4.4	11
12	Irregular Lipomatous Extremity Tumor. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1718.	7.4	0
13	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018, 17, 722-727.	2.6	9
14	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	2.1	28
15	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1154-1161.	1.3	35
16	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	2.6	57
17	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	2.6	13
18	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	7.2	56

#	ARTICLE	IF	CITATIONS
19	Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 967-972.	2.6	13
20	Long-term outcomes of cement in cement technique for revision endoprosthesis surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 443-450.	1.7	9
21	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	2.6	40
22	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	2.6	30
23	Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , 2018, 63, 278-283.	1.6	25
24	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	2.1	29
25	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	2.1	18
26	Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018, 54, 144-149.	2.2	8
27	Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	2.1	27
28	Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	2.6	6
29	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	17.1	5
30	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	2.6	14
31	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	2.2	18
32	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	2.6	14
33	Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	3.2	11
34	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	1.8	22
35	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018, 9, 915-923.	1.8	42
36	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	1.8	35

#	ARTICLE	IF	CITATIONS
37	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	1.8	22
38	Tumor-Targeting <i>Salmonella typhimurium</i> A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	2.6	53
39	Potential of immunotherapy for sarcoma. <i>Cancer</i> , 2017, 123, 1488-1489.	4.1	4
40	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2739-2743.	2.6	34
41	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	2.6	30
42	Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3367-3371.	2.6	14
43	Intra-arterial administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017, 16, 1164-1170.	2.6	49
44	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	2.6	37
45	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , 2017, 16, 1046-1052.	2.6	38
46	Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. <i>Cell Cycle</i> , 2017, 16, 91-94.	2.6	41
47	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 361-365.	2.6	34
48	Tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017, 8, 8035-8042.	1.8	50
49	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.0	5
50	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 35630-35638.	1.8	77
51	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 75874-75880.	1.8	33
52	Toxicology and efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , 2017, 8, 54616-54628.	1.8	16
53	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 63353-63359.	1.8	24
54	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	1.8	48

#	ARTICLE	IF	CITATIONS
55	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017, 8, 85516-85525.	1.8	67
56	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	1.8	38
57	Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. <i>Anticancer Research</i> , 2017, 37, 4081-4084.	1.1	5
58	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016, 7, 71737-71743.	1.8	72
59	Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0160882.	2.5	93
60	Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor. <i>Human Pathology</i> , 2016, 54, 92-99.	2.0	11
61	Malignant Peripheral Nerve Sheath Tumor. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 789-802.	1.5	109
62	Sclerostin expression in skeletal sarcomas. <i>Human Pathology</i> , 2016, 58, 24-34.	2.0	7
63	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 64300-64308.	1.8	44
64	Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. <i>Oncotarget</i> , 2016, 7, 72860-72867.	1.8	15
65	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 85929-85936.	1.8	77
66	Tumor-targeting <i>Salmonella typhimurium</i> A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 12783-12790.	1.8	109
67	High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , 2016, 7, 33046-33054.	1.8	93
68	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	1.8	91
69	Diagnosis and management of synovial sarcoma. <i>Journal of Surgical Oncology</i> , 2008, 97, 314-320.	1.7	165
70	Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma. <i>Annals of Surgery</i> , 2007, 246, 105-113.	4.2	187
71	Advances in Chemotherapy for Patients with Extremity Soft Tissue Sarcoma. <i>Orthopedic Clinics of North America</i> , 2006, 37, 15-22.	1.2	24
72	Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2001, 19, 3203-3209.	1.6	296

#	ARTICLE	IF	CITATIONS
73	Surgical Resection and Intraperitoneal Chemotherapy for Recurrent Abdominal Sarcomas. <i>Annals of Surgical Oncology</i> , 1999, 6, 645-650.	1.5	73